Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CLDX | PRESS-RELEASE | neutral | 4/10 | Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold | Jun 10, 2026 |
| TEVA | PRESS-RELEASE | bullish | 6/10 | Teva closed its acquisition of Emalex Biosciences for $700M upfront plus up to $200M in milestones and sales-based royal | Jun 10, 2026 |
| LSTA | PRESS-RELEASE | bullish | 7/10 | Lisata Therapeutics announced that Kuva Acquisition Corp. has commenced a tender offer to acquire all outstanding shares | Jun 10, 2026 |
| IXHL | PRESS-RELEASE | mixed | 6/10 | Incannex Healthcare announced receipt of A$6.0M from the Australian R&D Tax Incentive program with an additional ~A$5.1M | Jun 10, 2026 |
| CGEM | PRESS-RELEASE | neutral | 4/10 | Cullinan Therapeutics released clinical data on two T cell engager programs (CLN-978 and velinotamig) for autoimmune dis | Jun 10, 2026 |
| RFL | PRESS-RELEASE | bullish | 7/10 | Rafael Holdings announced the last patient completed the final 96-week visit in its pivotal Phase 3 TransportNPC study f | Jun 10, 2026 |
| STTK | PRESS-RELEASE | bearish | 6/10 | Shattuck Labs priced a public offering of 10,879,376 common shares at $4.00/share and pre-funded warrants for 7,870,624 | Jun 10, 2026 |
| TNGX | PRESS-RELEASE | bearish | 6/10 | Tango Therapeutics priced a $600M underwritten offering of 18.2M common shares and pre-funded warrants at $30/share, wit | Jun 9, 2026 |
| TVGN | PRESS-RELEASE | neutral | 5/10 | Tevogen Bio announced a healthcare services initiative exploring potential acquisitions of a Management Services Organiz | Jun 9, 2026 |
| IRON | PRESS-RELEASE | bullish | 6/10 | Disc Medicine announced alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the ba | Jun 9, 2026 |
| ACTU | PRESS-RELEASE | bullish | 7/10 | Actuate Therapeutics announced that its lead drug elraglusib will be evaluated in the BEACON2 platform trial for relapse | Jun 9, 2026 |
| ATHE | PRESS-RELEASE | bullish | 7/10 | Alterity Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, achieving alignment on the pivotal Pha | Jun 9, 2026 |
| IVVD | PRESS-RELEASE | neutral | 4/10 | Invivyd dosed first participants in the LIBERTY Phase 3 trial evaluating VYD2311 (mAb) vs. mRNA COVID-19 vaccine, with t | Jun 9, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis announced the first patient randomized in PREDICT-1, a genotype-based registrational trial for Licaminlimab in dr | Jun 9, 2026 |
| AIM | PRESS-RELEASE | bullish | 5/10 | AIM ImmunoTech announced completion of enrollment in the Phase 2 DURIPANC study combining Ampligen with Imfinzi for meta | Jun 8, 2026 |
| CRMD | PRESS-RELEASE | bullish | 7/10 | CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity and infringement of | Jun 8, 2026 |
| VOR | PRESS-RELEASE | bullish | 7/10 | Vor Biopharma announced that China's NMPA conditionally approved telitacicept for IgA nephropathy, the first BAFF/APRIL- | Jun 8, 2026 |
| HYPD | PRESS-RELEASE | mixed | 6/10 | Hyperion DeFi reported Q1 2026 EPS of $0.26, a 25.7% miss vs the $0.35 consensus, with revenue of $450K. The company rei | Jun 8, 2026 |
| BCDA | PRESS-RELEASE | bearish | 7/10 | BioCardia reported Q1 2026 EPS of -$0.21, missing the consensus estimate of -$0.18 by 16.7%. The company also disclosed | Jun 8, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings subsidiary NorthStrive Defense Tech signed a binding term sheet for an exclusive, worldwide, sublicensable | Jun 8, 2026 |
| KYMR | PRESS-RELEASE | bullish | 6/10 | Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, show | Jun 8, 2026 |
| ARTV | PRESS-RELEASE | bullish | 7/10 | Artiva Biotherapeutics presented positive clinical data for AlloNK (AB-101) at EULAR 2026, including a 71% ACR50 respons | Jun 8, 2026 |
| LYEL | PRESS-RELEASE | bullish | 7/10 | Lyell Immunopharma announced updated safety data from its Phase 1 trial of LYL273 in metastatic colorectal cancer, showi | Jun 8, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech announced FDA acceptance of its BLA for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab), | Jun 8, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech announced FDA acceptance of its BLA for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) f | Jun 8, 2026 |
| NRIX | PRESS-RELEASE | bullish | 8/10 | Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral | Jun 8, 2026 |
| LENZ | PRESS-RELEASE | bullish | 6/10 | LENZ Therapeutics announced that Everest Medicines has acquired the rights to develop and commercialize VIZZ (LNZ100) in | Jun 7, 2026 |
| BMEA | PRESS-RELEASE | bullish | 6/10 | Biomea Fusion presented new clinical and translational data for icovamenib at ADA 2026, showing durable HbA1c improvemen | Jun 5, 2026 |
| KLRA | PRESS-RELEASE | bullish | 7/10 | Kailera Therapeutics and Hengrui Pharma presented positive Phase 2 oral and Phase 1 injection data for ribupatide (GLP-1 | Jun 5, 2026 |
| JBIO | PRESS-RELEASE | bearish | 6/10 | Jade Biosciences closed a public offering of 11.5M shares at $15.00/share, raising $172.5M in gross proceeds. The procee | Jun 5, 2026 |